Related Experiment Video
Updated: Oct 20, 2025

Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Resistant type 2 amiodarone-induced thyrotoxicosis responsive to cholestyramine as an adjunctive therapy
Aisha Rummaan1, Maryam Maryam1, Awais Ali1
1The Dudley Group NHS Foundation Trust, Dudley, UK.
Abstract:
Amiodarone is a class 3 antiarrhythmic drug which may be associated with thyroid dysfunction. Amiodarone-induced thyrotoxicosis (AIT) is classified as type 1 (AIT 1; which may develop in the presence of latent autoimmune hyperthyroid condition) or type 2 (AIT 2; which develops in an apparently normal thyroid resulting from destructive thyroiditis). AIT 1 routinely requires treatment with thionamides, whereas AIT 2 is treated with steroids. Resistance to the conventional treatment of hyperthyroidism is not commonly found in clinical practice. This report discusses a case of AIT 2 resistant to conventional treatment. Despite being on high doses of carbimazole and steroids (prednisolone), the patient remained thyrotoxic. Cholestyramine, a bile salt sequestrant, was used as an adjunctive therapy resulting in significant clinical and biochemical improvement. The patient subsequently became euthyroid and is being followed up in endocrine clinic.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Atherosclerosis III: Management
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
